A Phase 3 interventional study of Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) and Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Completed at 107 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by Intergroupe Francophone du Myelome · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.
Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 2nd largest by enrollment of the 267 interventional ones that give a count, is one of 3 that started in 2015, is one of 42 in phase 3, and was the 210th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
Canadian Myeloma Research Group · Sites in Canada
Ages 65+
Peking University First Hospital · Sites in China
Ages 18–70
Stichting European Myeloma Network · Sites in Austria, Germany, Greece and 2 more countries
Ages 18–70
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
271 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 76 · Phase 2 176 · Phase 3 46 · Phase 4 8
First in 1999; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,085 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 267 interventional studies. Of the 194 that completed or were terminated, 94 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 271 have an industry lead sponsor. The 10 most frequent:
Intergroupe Francophone du Myelome is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome: 1 open now, 4 under way, 2 of them phase 3. Of 5 finished, 1 (20%) have results posted.
Among the 10 studies in Multiple Myeloma by Intergroupe Francophone du Myelome, this one is one of 2 that started in 2015, is one of 4 in phase 3, and was the 3rd registered.
Intergroupe Francophone du Myelome’s Multiple Myeloma studies by the year they started, since 2008.
9 of the studies testing bortezomib in Multiple Myeloma that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT05665140Phase 3University Hopsital Schleswig Holstein Campus LübeckExpression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | 2027-08 |
| NCT00734877Phase 3University of ArkansasUARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | 2027-09 |
| NCT02718833Massachusetts General HospitalA Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 271 studies testing bortezomib in Multiple Myeloma, from their registry updates:
Among Intergroupe Francophone du Myelome’s 10 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.
This is a randomized, open-label (identity of assigned treatment will be known to participants and study staff), 2-arm (2 treatment groups), multicenter study of daratumumab in participants diagnosed with previously untreated Multiple Myeloma who are eligible for high dose chemotherapy and autologous stem cell transplantation (transplantation of own bone marrow). Participants will be randomized (assigned by chance) to one of 2 treatment groups to either receive daratumumab plus bortezomib, thalidomide and dexamethasone or bortezomib, thalidomide and dexamethasone for induction (before transplantation) and consolidation (after transplantation) treatment. All responders will then be re-randomized (assigned by chance) to one of 2 treatment groups to receive maintenance treatment with daratumumab only or observation (no treatment). The study will include a 28-Day Screening Phase, a Treatment Phase of 6 treatment cycles (each cycle is 4 weeks in duration for total period of 30 weeks), and a Follow up Phase of 2 years. The total duration for each participant in the study will be approximately 138 weeks. The end of the study will occur approximately 5 years after the last participant is randomized in the second phase of the study. Disease assessments will be performed every 4 weeks in the first phase of the study and then every 8 weeks in the second phase of the study. Safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab
Observation
daratumumab
Drug: Daratumumab
Drug page: Bortezomib
Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
Also known as: Arm A Part 1
Drug pages: Bortezomib · Thalidomide · Dexamethasone · Daratumumab
Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
Also known as: Arm B Part 1
Daratumumab 16mg/kg every 8 weeks for 2 years
Also known as: Arm B Part 2
Post-Consolidation Stringent Complete Response (sCR) Rate
Post-consolidation sCR rate is defined as the percentage of ITT subjects who achieved or maintained sCR status within 30 days of Day 100 post Autologous Stem Cell Transplant (ASCT). The sCR status is assessed using the computerized algorithm according to IMWG response criteria, and must be achieved on or prior to start of subsequent therapies. Subjects must not die or progress by Day 100 post ASCT. According to the IMWG consensus recommendations for multiple myeloma treatment response criteria from 2006, the stringent complete response (sCR) was defined by a negative immunofixation on the serum and urine, and a disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow, plus normal free-light chain ratio and the absence of clonal bone marrow plasma cells by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
Time frame: At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT
Progression Free Survival (PFS) Post Completion of Maintenance Therapy
Progression Free Survival (PFS) post completion of maintenance therapy is defined as the duration from the date of second randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the completion of Maintenance therapy.
Time frame: From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).
Progression Free Survival (PFS) From First Randomization up to the End of the Study
Progression Free Survival (PFS) is defined as the duration from the date of first randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the end of the study
Time frame: From the date of first randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 80.1 months at the end of the study
| Milestone | VTd Only | DVTd Only * Arm/Group Title: Characters Remaining: 91 | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA |
|---|---|---|---|---|---|---|
| Started | 114 | 85 | 215 | 213 | 229 | 229 |
| Completed | 53 | 38 | 165 | 170 | 205 | 204 |
| Not completed | 61 | 47 | 50 | 43 | 24 | 25 |
| Withdrew: Death | 50 | 37 | 48 | 41 | 21 | 25 |
| Withdrew: Lost to follow-up | 5 | 3 | 1 | 1 | 3 | 0 |
| Withdrew: Consent withdrawn | 5 | 6 | 1 | 1 | 0 | 0 |
| Withdrew: Sponsor's decision | 1 | 1 | 0 | 0 | 0 | 0 |
Post-consolidation sCR rate is defined as the percentage of ITT subjects who achieved or maintained sCR status within 30 days of Day 100 post Autologous Stem Cell Transplant (ASCT). The sCR status is assessed using the computerized algorithm according to IMWG response criteria, and must be achieved on or prior to start of subsequent therapies. Subjects must not die or progress by Day 100 post ASCT. According to the IMWG consensus recommendations for multiple myeloma treatment response criteria from 2006, the stringent complete response (sCR) was defined by a negative immunofixation on the serum and urine, and a disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow, plus normal free-light chain ratio and the absence of clonal bone marrow plasma cells by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.
| Participants | Arm A Part 1 | Arm B Part 1 |
|---|---|---|
| Post-Consolidation Stringent Complete Response (sCR) Rate | 110 | 157 |
Progression Free Survival (PFS) post completion of maintenance therapy is defined as the duration from the date of second randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the completion of Maintenance therapy.
| Months | Arm A Part 2 | Arm B Part 2 |
|---|---|---|
| Progression Free Survival (PFS) Post Completion of Maintenance Therapy | 46.7 (40.0 to NA) | NA (NA to NA) |
Progression Free Survival (PFS) is defined as the duration from the date of first randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the end of the study
| Months | Arm A - Part 1 up to End of Study | Arm B - Part 1 up to End of Study |
|---|---|---|
| Progression Free Survival (PFS) From First Randomization up to the End of the Study | 52.8 (47.5 to 58.7) | 83.7 (70.2 to NA) |
Collected over AEs that started during the treatment until 30 days after the last dose of study treatment, approximately 59 months, except for secondary malignancies and deaths followed until the end of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VTd - Part 1 | 139/542 (25.6%) | 261/538 (48.5%) | 529/538 (98.3%) |
| DVTd - Part 1 | 83/543 (15.3%) | 264/536 (49.3%) | 534/536 (99.6%) |
| VTd-OBS - Part 2 | 48/215 (22.3%) | 35/215 (16.3%) | 170/215 (79.1%) |
| VTd-DARA - Part 2 | 41/211 (19.4%) | 58/211 (27.5%) | 194/211 (91.9%) |
| DVTd-OBS - Part 2 | 21/229 (9.2%) | 50/229 (21.8%) | 198/229 (86.5%) |
| DVTd-DARA - Part 2 | 25/229 (10.9%) | 43/229 (18.8%) | 205/229 (89.5%) |
| Event | VTd - Part 1 | DVTd - Part 1 | VTd-OBS - Part 2 | VTd-DARA - Part 2 | DVTd-OBS - Part 2 | DVTd-DARA - Part 2 |
|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 8/538 | 22/536 | 0/215 | 0/211 | 0/229 | 0/229 |
| PyrexiaGeneral disorders | 22/538 | 15/536 | 0/215 | 0/211 | 0/229 | 2/229 |
| PneumoniaInfections and infestations | 9/538 | 21/536 | 2/215 | 4/211 | 4/229 | 7/229 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 20/538 | 8/536 | 0/215 | 0/211 | 0/229 | 1/229 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 16/538 | 12/536 | 0/215 | 1/211 | 0/229 | 0/229 |
| Peripheral Sensory NeuropathyNervous system disorders | 16/538 | 11/536 | 0/215 | 0/211 | 0/229 | 0/229 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/538 | 12/536 | 1/215 | 0/211 | 0/229 | 0/229 |
| Febrile Bone Marrow AplasiaBlood and lymphatic system disorders | 12/538 | 7/536 | 0/215 | 0/211 | 0/229 | 0/229 |
| SepsisInfections and infestations | 11/538 | 7/536 | 1/215 | 0/211 | 0/229 | 1/229 |
| Lung DisorderRespiratory, thoracic and mediastinal disorders | 6/538 | 10/536 | 0/215 | 0/211 | 0/229 | 0/229 |
| Event | VTd - Part 1 | DVTd - Part 1 | VTd-OBS - Part 2 | VTd-DARA - Part 2 | DVTd-OBS - Part 2 | DVTd-DARA - Part 2 |
|---|---|---|---|---|---|---|
| Peripheral Sensory NeuropathyNervous system disorders | 340/538 | 325/536 | 24/215 | 31/211 | 27/229 | 39/229 |
| ConstipationGastrointestinal disorders | 255/538 | 271/536 | 2/215 | 10/211 | 6/229 | 7/229 |
| BronchitisInfections and infestations | 79/538 | 107/536 | 71/215 | 77/211 | 63/229 | 93/229 |
| AstheniaGeneral disorders | 159/538 | 176/536 | 27/215 | 35/211 | 26/229 | 26/229 |
| Oedema PeripheralGeneral disorders | 154/538 | 166/536 | 8/215 | 9/211 | 9/229 | 13/229 |
| NauseaGastrointestinal disorders | 129/538 | 159/536 | 2/215 | 33/211 | 4/229 | 10/229 |
| NeutropeniaBlood and lymphatic system disorders | 83/538 | 149/536 | 6/215 | 7/211 | 4/229 | 5/229 |
| PyrexiaGeneral disorders | 104/538 | 133/536 | 7/215 | 20/211 | 17/229 | 18/229 |
| ParaesthesiaNervous system disorders | 114/538 | 127/536 | 4/215 | 21/211 | 10/229 | 15/229 |
| ThrombocytopeniaBlood and lymphatic system disorders | 72/538 | 109/536 | 4/215 | 7/211 | 4/229 | 10/229 |
| Age, Continuous(years) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| Mean | 57.7 ± 6.36 | 57.8 ± 7.5 | 56 ± 6.96 | 56.3 ± 7.38 | 56.8 ± 6.83 | 56.4 ± 6.79 | 56.6 ± 6.98 |
| Sex: Female, Male(Participants) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| Female | 42 | 37 | 94 | 87 | 96 | 94 | 450 |
| Male | 72 | 48 | 121 | 126 | 133 | 135 | 635 |
| Race and Ethnicity Not Collected(Participants) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | 0 |
| Region of Enrollment(participants) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| BELGIUM | 15 | 5 | 11 | 18 | 23 | 17 | 89 |
| FRANCE | 70 | 64 | 191 | 169 | 177 | 183 | 854 |
| NETHERLANDS | 29 | 16 | 13 | 26 | 29 | 29 | 142 |
| Baseline ISS Stage(participants) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| I | 47 | 25 | 88 | 93 | 83 | 96 | 432 |
| II | 52 | 41 | 96 | 85 | 118 | 96 | 488 |
| III | 15 | 19 | 31 | 35 | 28 | 37 | 165 |
| Baseline Type of Myeloma(participants) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| Biclonal | 1 | 2 | 10 | 8 | 5 | 5 | 31 |
| IgA | 15 | 14 | 46 | 43 | 36 | 37 | 191 |
| IgD | 3 | 1 | 3 | 7 | 2 | 2 | 18 |
| IgG | 79 | 54 | 126 | 128 | 159 | 138 | 684 |
| IgM | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
| Kappa | 11 | 9 | 17 | 18 | 17 | 27 | 99 |
| Lambda | 3 | 5 | 10 | 7 | 8 | 17 | 50 |
| Negative immunofixation | 2 | 0 | 2 | 1 | 2 | 2 | 9 |
| Time since initial diagnosis to randomization (months)(months) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| Mean | 1.6 ± 2.65 | 1.3 ± 0.96 | 1.2 ± 0.86 | 1.2 ± 0.87 | 1.2 ± 1.08 | 1.2 ± 0.95 | 1.2 ± 1.25 |
| Presence of diffuse myeloma-related osteopenia(participants) | VTd Only | DVTd Only | VTd-OBS | VTd-DARA | DVTd-OBS | DVTd-DARA | Total |
|---|---|---|---|---|---|---|---|
| No | 100 | 76 | 197 | 194 | 203 | 208 | 978 |
| Yes | 14 | 9 | 18 | 17 | 25 | 19 | 102 |
| Missing | 0 | 0 | 0 | 2 | 1 | 2 | 5 |
2 further baseline measures are reported on the registry.
Showing the first 100 of 107 sites across 3 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2015 to primary completion in Aug 2020, 59 months.
Results were first posted in Apr 2025, 4 years 7 months after primary completion.
Of 71 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's 59 months is below that.
Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bortezomib · Thalidomide · Dexamethasone · Daratumumab
Intergroupe Francophone du Myelome